Latest market price
15.93
+0.32+2.05%
AVTRQT72Avantor, Inc.·NYSE
15.93+2.05%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E31.22EPS (ttm)0.50Insider Own1.93%Shs Outstand677.62MPerf Week-9.72%
Market Cap10.58BForward P/E17.56EPS next Y0.89Insider Trans0.08%Shs Float659.03MPerf Month1.76%
Enterprise Value13.80BPEG4.32EPS next Q0.23Short Float5.26%Perf Quarter14.11%
Income336.00MP/S1.59EPS this Y-9.28%Short Ratio3.80Perf Half Y95.37%
Sales6.63BP/B1.81EPS next Y8.78%ROA2.90%Short Interest34.65MPerf YTD36.21%
Book/sh8.61P/C22.79EPS next 5Y7.22%ROE5.96%52W High17.45 -8.71%Perf Year41.27%
Cash/sh0.68P/FCF24.09EPS past 3/5Y—ROIC4.88%52W Low7.27 119.12%Perf 3Y-20.03%
Dividend Est.—EV/EBITDA15.18Sales past 3/5Y-4.46% 0.49%Gross Margin31.59%Volatility3.89% 3.30%Perf 5Y-58.81%
Dividend TTM—EV/Sales2.08EPS Y/Y TTM—Oper. Margin7.58%ATR (14)0.54Perf 10Y—
Dividend Ex-Date—Quick Ratio1.27Sales Y/Y TTM0.91%Profit Margin5.08%RSI (14)43.21Recom2.77
Dividend Gr. 3/5Y—Current Ratio1.89EPS Q/Q0.00%SMA20-3.98%Beta0.95Target Price14.55
Payout0.00%Debt/Eq0.63Sales Q/Q4.56%SMA500.62%Rel Volume1.08Prev Close15.61
Employees13,500LT Debt/Eq0.63EarningsFeb 10SMA20039.22%Avg Volume8.67MPrice15.93
IPO DateMay 17, 2019Option/ShortYes / YesEPS/Sales Surpr.5.24% 3.37%Net Debt/EBITDA3.54Volume9,403,546Change2.05%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedDeutsche BankHold$13 → $17
Oct-29-26ReiteratedRobert W. Baird$17 → $18
Oct-29-26ReiteratedBarclaysUnderweight$7.00 → $16
Oct-28-26ReiteratedEvercore ISIIn Line$15 → $17
Sep-09-26ReiteratedUBSNeutral$8.00 → $16
Jul-30-26ReiteratedDeutsche BankHold$11 → $13
Jul-30-26ReiteratedRBC CapitalSector Perform$9.00 → $14
Jul-30-26ReiteratedMorgan StanleyEqual Weight$10 → $14
Jul-29-26ReiteratedJefferiesUnderperform$8.00 → $13
Jul-06-26ReiteratedEvercore ISI GroupIn Line$10 → $11
Latest News· Times ET
Oct-30-26
Oct-28-26
Oct-26-26
Oct-21-26
Oct-14-26
Oct-14-2607:02AM
Oct-13-26
Oct-07-26
Company

Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue6,6356,5526,7846,967—————
Cost of Goods Sold Incl. D&A4,5404,4134,5044,603—————
Gross Profit2,0972,1392,2792,364—————
Selling, General and Administrative Excl. Other1,2021,5961,6411,507—————
Research and Development
0000—————
Other Operating Expense392790-446160—————
Operating Income503-2461,085696—————
Interest Expense174170219285—————
Unusual Expense
—————————
Non-Operating Income (Expense)-13-25-12-1—————
Net Income Before Taxes316-441854411—————
Income Taxes-228914289—————
Consolidated Net Income336-530712321—————
Net Income From Continuing Operations336-530712321—————
Net Income336-530712321—————
EPS (Recurring)0.50-0.781.050.48—————
EPS (Basic, Before Extraordinaries)0.50-0.781.050.48—————
EPS (Diluted)0.50-0.781.040.47—————
EBITDA9091391,4781,098—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio31.86—20.2648.57—————
Price To Sales Ratio1.631.192.112.22—————
Gross Margin31.6132.6533.5933.93—————
Operating Margin7.58-3.7515.999.99—————
Net Margin5.06-8.0910.504.61—————
Shares Outstanding677678680676—————
Market Capitalization10,7857,77014,32815,433—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$18.77$15.56$12.35$9.14$5.93● Close Price0.00M0.97M1.94M2.91M3.88MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
LUCIER GREGORY TDirectorMay 08 '26Buy8.3210,00083,20060,000May 11
Dingemans SimonDirectorMay 01 '26Buy8.1425,000203,50025,000May 05
MEHRA SANJEEV KDirectorMar 10 '26Buy8.01125,0001,001,250475,000Mar 11
LUCIER GREGORY TDirectorFeb 19 '26Buy9.1650,000458,00050,000Feb 23
SUMME GREGORY LDirectorFeb 12 '26Buy9.40100,000940,000400,000Feb 12
MEHRA SANJEEV KDirectorDec 05 '25Buy11.09350,0003,881,500350,000Dec 09
Ligner EmmanuelPresident and CEONov 17 '25Buy11.3587,500993,125283,424Nov 17
SUMME GREGORY LDirectorOct 30 '25Buy11.25100,0001,125,000300,000Oct 31
SUMME GREGORY LDirectorAug 21 '25Buy12.56100,0001,256,000200,000Aug 22
Eck Steven WSVP & Chief Accounting OfficerAug 05 '25Sale11.393,47639,59255,068Aug 06
SUMME GREGORY LDirectorMay 23 '25Buy12.5030,000375,000100,000May 27
SUMME GREGORY LDirectorMay 22 '25Buy12.6520,000253,00070,000May 22
SUMME GREGORY LDirectorMay 07 '25Buy12.0025,000300,00050,000May 09
Massaro Joseph RDirectorApr 29 '25Buy12.308,10099,63035,038Apr 29
SUMME GREGORY LDirectorApr 28 '25Buy12.5025,000312,50025,000Apr 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.